Investor Relations

AVEO Oncology is a biopharmaceutical company committed to developing targeted therapies through biomarker-driven insights to provide substantial improvements in patient outcomes where significant unmet medical needs exist. AVEO’s proprietary Human Response Platform™ has delivered unique insights into cancer and related disease biology that are being leveraged in the clinical development of its therapeutic candidates.

NASDAQ | AVEO (Common Stock)
$1.84 + 0.12
Stock chart for: AVEO.O.  Currently trading at $1.84 with a 52 week high of $2.02 and a 52 week low of $0.61.
04/17/15 4:00 p.m. ET
Data Provided by Thomson Reuters